398 related articles for article (PubMed ID: 28273064)
1. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Guerriero JL; Sotayo A; Ponichtera HE; Castrillon JA; Pourzia AL; Schad S; Johnson SF; Carrasco RD; Lazo S; Bronson RT; Davis SP; Lobera M; Nolan MA; Letai A
Nature; 2017 Mar; 543(7645):428-432. PubMed ID: 28273064
[TBL] [Abstract][Full Text] [Related]
2. Repolarizing macrophages improves breast cancer therapy.
Cassetta L; Pollard JW
Cell Res; 2017 Aug; 27(8):963-964. PubMed ID: 28429765
[TBL] [Abstract][Full Text] [Related]
3. Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
Zhang W; Guan Y; Bayliss G; Zhuang S
Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1015-F1026. PubMed ID: 33017186
[TBL] [Abstract][Full Text] [Related]
4. TMP195 Exerts Antitumor Effects on Colorectal Cancer by Promoting M1 Macrophages Polarization.
Han Y; Sun J; Yang Y; Liu Y; Lou J; Pan H; Yao J; Han W
Int J Biol Sci; 2022; 18(15):5653-5666. PubMed ID: 36263186
[TBL] [Abstract][Full Text] [Related]
5. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
6. Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Alhudaithi SS; Almuqbil RM; Zhang H; Bielski ER; Du W; Sunbul FS; Bos PD; da Rocha SRP
Mol Pharm; 2020 Dec; 17(12):4691-4703. PubMed ID: 33170724
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
Cuccarese MF; Dubach JM; Pfirschke C; Engblom C; Garris C; Miller MA; Pittet MJ; Weissleder R
Nat Commun; 2017 Feb; 8():14293. PubMed ID: 28176769
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
DeNardo DG; Brennan DJ; Rexhepaj E; Ruffell B; Shiao SL; Madden SF; Gallagher WM; Wadhwani N; Keil SD; Junaid SA; Rugo HS; Hwang ES; Jirström K; West BL; Coussens LM
Cancer Discov; 2011 Jun; 1(1):54-67. PubMed ID: 22039576
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S
Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365
[TBL] [Abstract][Full Text] [Related]
10. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
[TBL] [Abstract][Full Text] [Related]
11. Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances
Moreira JD; Koch BEV; van Veen S; Walburg KV; Vrieling F; Mara Pinto Dabés Guimarães T; Meijer AH; Spaink HP; Ottenhoff THM; Haks MC; Heemskerk MT
Front Immunol; 2020; 11():36. PubMed ID: 32117228
[TBL] [Abstract][Full Text] [Related]
12. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
14. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
15. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
[TBL] [Abstract][Full Text] [Related]
16. Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype.
Deligne C; Murdamoothoo D; Gammage AN; Gschwandtner M; Erne W; Loustau T; Marzeda AM; Carapito R; Paul N; Velazquez-Quesada I; Mazzier I; Sun Z; Orend G; Midwood KS
Cancer Immunol Res; 2020 Mar; 8(3):368-382. PubMed ID: 31941671
[TBL] [Abstract][Full Text] [Related]
17. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.
Myers DR; Abram CL; Wildes D; Belwafa A; Welsh AMN; Schulze CJ; Choy TJ; Nguyen T; Omaque N; Hu Y; Singh M; Hansen R; Goldsmith MA; Quintana E; Smith JAM; Lowell CA
Front Immunol; 2020; 11():576310. PubMed ID: 33133093
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
[TBL] [Abstract][Full Text] [Related]
19. Activation of innate immunity to reduce lung metastases in breast cancer.
Jordan JL; Nowak A; Lee TD
Cancer Immunol Immunother; 2010 May; 59(5):789-97. PubMed ID: 19956948
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability.
Asare Y; Campbell-James TA; Bokov Y; Yu LL; Prestel M; El Bounkari O; Roth S; Megens RTA; Straub T; Thomas K; Yan G; Schneider M; Ziesch N; Tiedt S; Silvestre-Roig C; Braster Q; Huang Y; Schneider M; Malik R; Haffner C; Liesz A; Soehnlein O; Bernhagen J; Dichgans M
Circ Res; 2020 Aug; 127(6):811-823. PubMed ID: 32546048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
